journal
MENU ▼
Read by QxMD icon Read
search

Journal of Hepatology

journal
https://www.readbyqxmd.com/read/29233630/higher-risk-of-renal-disease-in-chronic-hepatitis-c-patients-antiviral-therapy-survival-benefit-in-patients-on-hemodialysis
#1
Jonas Söderholm, Charlotta Millbourn, Katharina Büsch, Jan Kövamees, Robert Schvarcz, Karin Lindahl, Annette Bruchfeld
BACKGROUND & AIMS: Several studies have shown that chronic hepatitis C (CHC) infection has a negative impact on kidney function, as well as survival, in patients with chronic kidney disease (CKD) or on hemodialysis (HD). The aim of this nationwide registry study was to describe renal disease in Swedish CHC patients METHODS: In the present study, patients were identified for CHC (B18.2) and CKD (N18) according to the International Classification of Diseases (ICD)-10 in the nationwide Swedish inpatient care day surgery (1997-2013) and non-primary outpatient care (2001-2013) patient registries...
December 9, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29233629/achieving-hepatitis-c-elimination-in-europe-to-treatment-scale-up-and-beyond
#2
EDITORIAL
M Hellard, N Scott, R Sacks Davis, A Pedrana
No abstract text is available yet for this article.
December 9, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29229584/eliminating-hepatitis-c-within-low-income-countries-the-need-to-cure-genotypes-4-5-6
#3
REVIEW
Tarik Asselah, Tarek Hassanein, Imam Waked, Abdellah Mansouri, Geoffrey Dusheiko, Edward Gane
Around 70 to 100 million people are chronically infected with HCV worldwide. HCV anti-viral drug development has been remarkable and this revolution led to several direct-acting antiviral agents achieving an HCV cure after only 8-12 weeks of treatment duration. Drug development has focused first on HCV genotype 1 infection, since it was the most prevalent worldwide, although clinical trials included all genotypes prevalent in the US and Europe. Because the earliest in vitro assays utilised the GT 1b and 2 replicons, the initial classes of direct acting antivirals (protease inhibitors, non-nucleotide polymerase inhibitors) were genotype 1-specific, albiet had an effect on other less prevalent genotypes...
December 8, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29223512/nafld-the-evolving-landscape
#4
EDITORIAL
Jacob George, Quentin Anstee, Vlad Ratziu, Arun Sanyal
No abstract text is available yet for this article.
December 6, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29223371/planning-and-prioritizing-direct-acting-antivirals-treatment-for-hcv-patients-in-countries-with-limited-resources-lessons-from-the-egyptian-experience
#5
Aisha Elsharkawy, Maissa El Raziky, Wafaa El Akel, Kadry El Saeed, Rasha Eletreby, Mohamed Hassany, Manal Hamdy El-Sayed, Khaled Kabil, Sohier A Ismail, Magdy El-Serafy, Ashraf Omar Abdelaziz, Mohamed Kamal Shaker, Ayman Yosry, Wahid Doss, Yehia El Shazly, Gamal Esmat, Imam Waked
BACKGROUND AND AIM: The introduction of direct acting antivirals for HCV in Egypt led to massive treatment uptake to become the largest HCV treatment program worldwide. The aim of this paper is to present the Egyptian experience in planning and prioritizing mass treatment for HCV patients, highlighting the difficulties and limitations of the program as guide to other countries of similar limited resources. METHODS: Baseline data of 337,042 patients who started treatment from October 2014 to March 2016 were grouped into three equal time intervals of 6 months each...
December 6, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29223370/four-weeks-of-ledipasvir-sofosbuvir-and-ribavirin-with-or-without-pegylated-interferon-for-chronic-hepatitis-c-in-non-cirrhotic-people-who-inject-drugs-a-randomized-trial
#6
LETTER
Anne L H Øvrehus, Henrik Krarup, Inge Birkemose, Dorte K Holm, Belinda Mössner, Anja Ernst, Peer B Christensen
No abstract text is available yet for this article.
December 6, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29223369/a-critical-review-of-endpoints-for-non-cirrhotic-nash-therapeutic-trials
#7
REVIEW
Vlad Ratziu
Non-alcoholic steatohepatitis is a disease without a single, specific, diagnostic marker, hence multiple indicators are required to measure therapeutic efficacy. Moreover, drug candidates for non-alcoholic steatohepatitis target many distinct mechanisms that are believed to promote hepatic injury. Therefore, a wide range of endpoints must be reached, sequentially, as required by the drug development process. Some of these endpoints validate the mechanism of action, others are used to anticipate histological efficacy...
December 6, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29221887/resistance-analysis-in-patients-with-genotype-1-6-hcv-infection-treated-with-sofosbuvir-velpatasvir-in-the-phase-3-studies
#8
Christophe Hezode, Nancy Reau, Evguenia S Svarovskaia, Brian P Doehle, Ragavi Shanmugam, Hadas Dvory-Sobol, Charlotte Hedskog, John McNally, Anu Osinusi, Diana M Brainard, Michael D Miller, Hongmei Mo, Stuart K Roberts, Jacqueline G O'Leary, Stephen D Shafran, Stefan Zeuzem
BACKGROUND & AIMS: The fixed dose combination of sofosbuvir/velpatasvir was highly efficacious in genotype (GT) 1-6 HCV infected patients in the ASTRAL studies. This analysis evaluated the impact of baseline resistance-associated substitutions (RASs) on treatment outcome and emergence of RASs in HCV GT1-6 infected patients treated with sofosbuvir/velpatasvir. METHODS: NS5A and NS5B deep sequencing was performed at baseline for all patients in the ASTRAL 1-3, ASTRAL-5 and POLARIS-2-3 studies treated with sofosbuvir/velpatasvir for 12 weeks (n=1778) and at the time of relapse...
December 5, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29221886/a-model-including-sarcopenia-surpasses-the-meld-score-in-predicting-waiting-list-mortality-in-cirrhotic-liver-transplant-candidates
#9
Jeroen Laurens Ad van Vugt, Louise Johanna Maria Alferink, Stefan Buettner, Marcia Patricia Gaspersz, Daphne Bot, Sarwa Darwish Murad, Shirin Feshtali, Peter Martinus Adranius van Ooijen, Wojciech Grzegorz Polak, Robert Jan Porte, Bart van Hoek, Aad Pieter van den Berg, Herold Johnny Metselaar, Jan Nicolaas Maria IJzermans
BACKGROUND AND AIMS: Frail patients with low MELD scores may be underprioritised. Low skeletal muscle mass (i.e. sarcopenia) has been identified as risk factor for waiting list mortality and a recent study proposed to incorporate sarcopenia in the MELD score (i.e. MELD-Sarcopenia score). We aimed to investigate the association between sarcopenia and waiting list mortality, and to validate the MELD-Sarcopenia score (i.e. MELD+10.35∗Sarcopenia). METHODS: We identified consecutive patients with cirrhosis listed for liver transplantation in the Eurotransplant registry between 2007-2014 and measured skeletal muscle mass on computed tomography (CT)...
December 5, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29217272/inhibition-of-hepatitis-b-virus-gene-expression-a-step-towards-functional-cure
#10
EDITORIAL
Fabien Zoulim
No abstract text is available yet for this article.
December 4, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29208489/relaxing-access-to-liver-transplantation-with-living-donation-a-foolish-move-or-a-time-to-change
#11
EDITORIAL
John G O'Grady
No abstract text is available yet for this article.
December 2, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29203392/role-of-imaging-based-biomarkers-in-nafld-recent-advances-in-clinical-application-and-future-research-directions
#12
REVIEW
Rohit Loomba
Nonalcoholic fatty liver disease (NAFLD) is a major public health problem afflicting approximately 1 billion individuals worldwide. Liver biopsy is considered the gold standard to assess severity of liver disease in patients with NAFLD. However, it is invasive, has high inter-observer variability, and is associated with adverse effects, including pain, infection, and rarely death. It is also impractical due to the large number of individuals who have NAFLD. Therefore, there is a strong need for the non-invasive assessment of disease severity in NAFLD...
December 1, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29191459/impact-of-real-time-metabolomics-in-liver-transplantation-graft-evaluation-and-donor-recipient-matching
#13
Francois Faitot, Camille Besch, Stephanie Battini, Elisa Ruhland, Mihaela Onea, Pietro Addeo, Marie-Lorraine Woehl-Jaeglé, Bernard Ellero, Philippe Bachellier, Izzie-Jacques Namer
BACKGROUND AND AIMS: The purpose of this study was to evaluate the potential value of high-resolution magic-angle-spinning nuclear magnetic resonance (HR-MAS-NMR) metabolomic analysis of back-table biopsies for the prediction of early allograft dysfunction and donor-recipient matching. Indeed there is an emerging need to assess the metabolic state of liver allograft especially in the novel setting of machine perfusion preservation and DCD grafts. HR-MAS-NMR could be a useful tool in this setting as it can extemporaneously provide untargeted metabolic profile...
November 27, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29180000/usefulness-of-biochemical-remission-and-transient-elastography-in-monitoring-disease-course-in-autoimmune-hepatitis
#14
Johannes Hartl, Hanno Ehlken, Marcial Sebode, Moritz Peiseler, Till Krechl, Roman Zenouzi, Johann von Felden, Christina Weiler-Normann, Christoph Schramm, Ansgar W Lohse
BACKGROUND: Liver fibrosis regression but also progression may occur in patients with autoimmune hepatitis (AIH) under treatment. There is a need for non-invasive surrogate markers for fibrosis development in AIH to better guide immunosuppressive treatment. AIMS: The aims of the study were to assess the impact of complete biochemical remission defined as normalisation of transaminases and IgG on histological activity and fibrosis development, and the value of repeat transient elastography (TE) measurement for monitoring disease progression in AIH...
November 24, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29175244/early-liver-transplantation-for-alcoholic-hepatitis-ready-for-primetime
#15
EDITORIAL
Maddie Kubiliun, Suraj J Patel, Chin Hur, Jules L Dienstag, Jay Luther
No abstract text is available yet for this article.
November 24, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29175243/the-molecular-functions-of-hepatocyte-nuclear-factors-in-and-beyond-the-liver
#16
REVIEW
Hwee Hui Lau, Natasha Hui Jin Ng, Larry Sai Weng Loo, Joanita Jasmen, Adrian Kee Keong Teo
The hepatocyte nuclear factors (HNFs) namely HNF1α/β, HNF3α/β/γ, HNF4α/γ and HNF6 are expressed in a variety of tissues/organs such as the liver, pancreas and kidney, in a spatial and temporal manner to regulate embryonic development and subsequently the development of multiple tissues during adulthood. Though the HNFs were initially individually identified due to their roles in the liver, numerous studies have now revealed that the HNFs cross-regulate one another and exhibit synergistic relationships in the regulation of tissue development and function...
November 23, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29175242/association-of-nonalcoholic-steatohepatitis-with-subclinical-myocardial-dysfunction-in-non-cirrhotic-patients
#17
Yong-Ho Lee, Kwang Joon Kim, Myung Eun Yoo, Gyuri Kim, Hye-Jin Yoon, Kwanhyeong Jo, Jong-Chan Youn, Mijin Yun, Jun Yong Park, Chi Young Shim, Byung-Wan Lee, Seok-Min Kang, Jong-Won Ha, Bong-Soo Cha, Eun Seok Kang
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) is associated with increased cardiovascular risk. Among categories of NAFLD, hepatic fibrosis is most likely to affect mortality. Myocardial function and its energy metabolism are tightly linked, which might be altered by an insulin resistant condition such as NAFLD. We investigated whether hepatic steatosis and fibrosis were associated with myocardial dysfunction relative to myocardial glucose uptake. METHODS: 308 patients (190 without NAFLD, 118 with NAFLD) were studied...
November 23, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29175241/clinical-management-of-polycystic-liver-disease
#18
REVIEW
René M M van Aerts, Liyanne F M van de Laarschot, Jesus M Banales, Joost P H Drenth
In this Grand Round we present a typical case of a woman with polycystic liver disease (PLD). This case prompts questions which both patients and clinicians may face in clinical practice. This article aims to provide guidance to clinicians in the care of PLD patients in relation to recent key development in the field. We discuss the latest novelties in pathophysiology, natural course of disease, complications and treatment options. Finally, we discuss other potential new and effective therapies.
November 23, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29175240/reply-to-energy-drinks-and-adolescents-a-hepatic-health-hazard
#19
LETTER
Valerio Nobili, A Mosca, E Scorletti, Christopher D Byrne
No abstract text is available yet for this article.
November 23, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29175287/energy-drinks-and-adolescents-a-hepatic-health-hazard
#20
LETTER
Sophie Robin, Ryan Buchanan, Robin Poole
No abstract text is available yet for this article.
November 22, 2017: Journal of Hepatology
journal
journal
20153
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"